Stephen V Liu: ESMO23 – Dr. Solange Peters presents the PERLA randomized phase II study

Quoting Stephen V Liu, Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown University, on X/Twitter:

“ESMO23 – Dr. Solange Peters presents the PERLA randomized phase II study comparing two PD-1 inhibitors in NSCLC. Dostarlimab + chemotherapy versus pembrolizumab + chemotherapy. Some differences in dostarlimab binding – will that translate to an OS difference?”

Source: Stephen V Liu/Twitter